INSILICO MEDICINE

Alex Zhavoronkov, a computer scientist and longevity researcher, founded Insilico Medicine in 2014 with the thesis that AI could dramatically accelerate every step of drug discovery — from identifying disease targets to designing molecules to predicting clinical outcomes. Based in Hong Kong with research labs worldwide, Insilico built an end-to-end AI platform (Pharma.AI) that combines target discovery, molecule generation, and clinical trial prediction.

Pharma partnerships and internal drug pipeline. Insilico generates revenue through licensing deals with pharmaceutical companies that use its AI platform and through its own internal drug development programs.

Major partnerships include deals with Sanofi and other pharma companies. The company also aims to bring its own AI-discovered drugs to market.

Pharma.AI (end-to-end AI drug discovery platform). PandaOmics (target discovery using AI).

Chemistry42 (AI-powered molecule design). InClinico (clinical trial outcome prediction).

ISM001-055 (lead drug candidate for pulmonary fibrosis).

Clinical validation of AI-discovered drugs. Insilico's growth strategy centers on proving that AI-designed drugs work in human clinical trials.

The company's lead candidate (ISM001-055 for pulmonary fibrosis) entered Phase II trials — one of the first fully AI-discovered drugs to reach this stage. Each clinical milestone validates the platform and attracts more pharma partners.

Drug development is inherently risky — 90% of drugs that enter clinical trials fail. If Insilico's AI-discovered drugs fail in trials, it would damage the thesis that AI can accelerate drug discovery.

The company also competes with Recursion Pharmaceuticals, BenevolentAI, and big pharma companies building internal AI capabilities.

Backed by Warburg Pincus, B Capital Group, Lilly Asia Ventures, and various pharma-focused investors. The company has raised $407 million across multiple rounds.